Tabula Rasa HealthCare Inc (NASDAQ:TRHC) – Analysts at Cantor Fitzgerald decreased their FY2020 earnings per share estimates for Tabula Rasa HealthCare in a research report issued on Thursday, June 25th. Cantor Fitzgerald analyst S. Halper now expects that the company will earn ($0.37) per share for the year, down from their prior forecast of ($0.25). Cantor Fitzgerald has a “Overweight” rating and a $83.00 price objective on the stock.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.24. Tabula Rasa HealthCare had a negative return on equity of 3.01% and a negative net margin of 12.10%. The business had revenue of $72.80 million for the quarter, compared to analysts’ expectations of $71.76 million. During the same period in the previous year, the business posted $0.10 EPS. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year.
A number of other research firms have also weighed in on TRHC. SVB Leerink started coverage on Tabula Rasa HealthCare in a report on Monday, April 13th. They set an “outperform” rating and a $65.00 target price for the company. Benchmark reduced their target price on Tabula Rasa HealthCare from $90.00 to $84.00 and set a “buy” rating for the company in a report on Monday, May 11th. ValuEngine lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Tuesday, May 12th. Zacks Investment Research lowered Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a report on Wednesday, June 24th. Finally, BidaskClub lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Tuesday, May 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. Tabula Rasa HealthCare currently has an average rating of “Buy” and a consensus target price of $68.60.
TRHC stock opened at $53.68 on Monday. The company has a quick ratio of 2.20, a current ratio of 2.32 and a debt-to-equity ratio of 1.40. The firm has a market capitalization of $1.26 billion, a PE ratio of -31.21 and a beta of 1.17. Tabula Rasa HealthCare has a twelve month low of $33.04 and a twelve month high of $69.72. The stock has a 50-day simple moving average of $57.26 and a two-hundred day simple moving average of $54.48.
In related news, Director Gordon Tunstall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the director now owns 12,989 shares in the company, valued at $649,450. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Andrea Carolan Speers sold 4,520 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $60.00, for a total value of $271,200.00. Following the transaction, the chief accounting officer now owns 43,560 shares of the company’s stock, valued at approximately $2,613,600. The disclosure for this sale can be found here. Insiders sold 67,040 shares of company stock valued at $3,919,268 in the last quarter. Corporate insiders own 11.60% of the company’s stock.
Several institutional investors have recently made changes to their positions in TRHC. Artisan Partners Limited Partnership grew its stake in shares of Tabula Rasa HealthCare by 5.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,037,660 shares of the company’s stock worth $50,513,000 after acquiring an additional 56,500 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Tabula Rasa HealthCare by 29.3% during the fourth quarter. Macquarie Group Ltd. now owns 1,002,296 shares of the company’s stock valued at $48,792,000 after buying an additional 227,187 shares during the last quarter. Credit Suisse AG boosted its position in shares of Tabula Rasa HealthCare by 23.0% during the fourth quarter. Credit Suisse AG now owns 859,798 shares of the company’s stock valued at $41,855,000 after buying an additional 160,719 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Tabula Rasa HealthCare by 125.2% during the first quarter. Bank of New York Mellon Corp now owns 733,507 shares of the company’s stock valued at $38,354,000 after buying an additional 407,738 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Tabula Rasa HealthCare by 65.1% during the fourth quarter. Janus Henderson Group PLC now owns 688,003 shares of the company’s stock valued at $33,492,000 after buying an additional 271,218 shares during the last quarter.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Article: Retained Earnings
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.